Oncopeptides AB (Oncopeptides AB) EV-to-EBIT : -3.07 (As of Jun. 05, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Oncopeptides AB's Enterprise Value is $68.52 Mil. Oncopeptides AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-22.31 Mil. Therefore, Oncopeptides AB's EV-to-EBIT for today is -3.07.

The historical rank and industry rank for Oncopeptides AB's EV-to-EBIT or its related term are showing as below:

ONPPF' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.05 Med: -1.76 Max: 0.25
Current: -3.03

During the past 10 years, the highest EV-to-EBIT of Oncopeptides AB was 0.25. The lowest was -6.05. And the median was -1.76.

ONPPF's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.61 vs ONPPF: -3.03

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Oncopeptides AB's Enterprise Value for the quarter that ended in Mar. 2024 was $50.83 Mil. Oncopeptides AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-22.31 Mil. Oncopeptides AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -43.89%.

Oncopeptides AB EV-to-EBIT Historical Data

The historical data trend for Oncopeptides AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB EV-to-EBIT Chart

Oncopeptides AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-8.28

-6.72

-0.20

-2.26

-2.66

Oncopeptides AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-2.40	-1.92	-2.52	-2.66	-2.53

Competitive Comparison of Oncopeptides AB's EV-to-EBIT

For the Biotechnology subindustry, Oncopeptides AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncopeptides AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's EV-to-EBIT falls into.

Oncopeptides AB EV-to-EBIT Calculation

Oncopeptides AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	68.515	/	-22.312
	=	-3.07

Oncopeptides AB's current Enterprise Value is $68.52 Mil.
Oncopeptides AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.31 Mil.

Oncopeptides AB (OTCPK:ONPPF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Oncopeptides AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-22.312	/	50.834002253
	=	-43.89 %

Oncopeptides AB's Enterprise Value for the quarter that ended in Mar. 2024 was $50.83 Mil.
Oncopeptides AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.31 Mil.

Oncopeptides AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB (Oncopeptides AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OTCPK:ONPPF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden 0RN4:UK OND:Germany OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate melflufen (Ygalo), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.